

July 24, 2023

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received Permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation – Additional Indication) from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.

Through this approval, Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults.

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.

We request you to take the above intimation on record.

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary